Related Experiment Videos
Atrial natriuretic peptide in heart failure
R R Brandt1, R S Wright, M M Redfield
1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Insights
Atrial natriuretic peptide (ANP) increases in heart failure, acting as a diagnostic marker. However, the kidneys become unresponsive to ANP, contributing to sodium retention and disease progression.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Atrial natriuretic peptide (ANP) is a cardiac hormone regulating sodium balance and inhibiting the renin-angiotensin-aldosterone system.
- Congestive heart failure (CHF) involves sodium retention due to increased cardiac load and neurohumoral activation.
- Circulating ANP levels significantly rise in CHF, reflecting increased synthesis and release.
Purpose of the Study:
- To explore the role of ANP in early heart failure.
- To investigate the mechanisms behind renal hyporesponsiveness to ANP in CHF.
- To discuss therapeutic strategies targeting ANP action.
Main Methods:
- Review of existing literature on ANP in heart failure.
- Analysis of ANP's diagnostic and prognostic significance.
- Examination of factors contributing to renal ANP resistance.
Main Results:
- Elevated ANP levels serve as a key diagnostic and prognostic marker in CHF.
- In early CHF, ANP may help maintain a compensated state in asymptomatic left ventricular dysfunction.
- Despite high circulating ANP, kidneys in CHF exhibit hyporesponsiveness, retaining sodium.
Conclusions:
- The attenuated renal response to ANP in CHF is multifactorial, involving renal hypoperfusion and activation of counter-regulatory systems.
- Potentiating ANP's biologic actions presents a therapeutic avenue to delay CHF progression.
- Understanding ANP resistance is crucial for developing effective CHF treatments.
Abstract:
Atrial natriuretic peptide hormone of cardiac origin, which is released in response to atrial distension and serves to maintain sodium homeostasis and inhibit activation of the renin-angiotensin-aldosterone system. Congestive heart failure is a clinical syndrome characterized by increased cardiac volume and pressure overload with an inability to excrete a sodium load, which is associated with increased activity of systemic neurohumoral and local autocrine and paracrine mechanisms. Circulating atrial natriuretic peptide is greatly increased in congestive heart failure as a result of increased synthesis and release of this hormone. Atrial natriuretic peptide has emerged as an important diagnostic and prognostic serum marker in congestive heart failure. In early heart failure, it may play a key role in preserving the compensated state of asymptomatic left ventricular dysfunction. Despite increased circulating atrial natriuretic peptide in heart failure, the kidney retains sodium and is hyporesponsive to exogenous and endogenous atrial natriuretic peptide. The mechanism for the attenuated renal response is multifactorial and includes renal hypoperfusion, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems. Therapeutic strategies to potentiate the biologic actions of atrial natriuretic peptide may prolong the asymptomatic phase and delay progression to overt congestive heart failure.